Topics

Clinical Trials About "esophagectomy chemoradiation active surveillance Esophageal Cancer" RSS

13:19 EST 22nd January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "esophagectomy chemoradiation active surveillance Esophageal Cancer" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "esophagectomy chemoradiation active surveillance Esophageal Cancer" on BioPortfolio

We have published hundreds of esophagectomy chemoradiation active surveillance Esophageal Cancer news stories on BioPortfolio along with dozens of esophagectomy chemoradiation active surveillance Esophageal Cancer Clinical Trials and PubMed Articles about esophagectomy chemoradiation active surveillance Esophageal Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of esophagectomy chemoradiation active surveillance Esophageal Cancer Companies in our database. You can also find out about relevant esophagectomy chemoradiation active surveillance Esophageal Cancer Drugs and Medications on this site too.

Showing "esophagectomy chemoradiation active surveillance Esophageal Cancer" Clinical Trials 1–25 of 33,000+

Extremely Relevant

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).


Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer – Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)

A multicenter randomized comparison of primary esophagectomy against definitive chemoradiotherapy for the treatment of squamous esophageal cancer.

Surgery or Chemoradiation for Esophageal Cancer

The aim of this study is to compare outcomes in patients with operable squamous carcinoma of the esophagus who have received either surgery or definitive chemoradiation (CRT).


Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.

Robotic Versus Thoracolaparoscopic Esophagectomy for Esophageal Cancer

Esophageal cancer is a debilitating condition. The treatment involved is complex requiring a combination of chemotherapy and surgery in most cases. Complete removal of the tumor and the adjacent lymph nodes is of utmost importance in improving the survival. Lymph node yield following surgery helps in proper staging of the disease and is an important prognosticating variable. It is hypothesized that the lymph node yield following robotic esophagectomy is higher than that followi...

Mediastinoscopy-assisted Transhiatal Esophagectomy VS Minimally Invasive Esophagectomy for Esophageal Cancer

Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Although the incidence of esophageal cancer has been decreased significantly in the past two decades in China, the mortality rate is still in the fourth place of all cancers. The estimated new cases and deaths of esophageal cancer in China is 4,779,000 and 3,750,000 respectively in 2015. To reduce the incidence of postoperative complications and mortality of esophageal cancer, the optional of minima...

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. Sample size is 100 people (50 people in each group). In the intervention group, patients are going to inject an enoxaparin (40 mg) daily concurrent by chemo-radiation. Therefore patients with esophageal cancer are going to assign randomly to control group (only chemo-radiotherapy) and interven...

A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

The purpose of this study is to test 2 different methods of surgery to remove cancer in the esophagus. This research is being done to see whether removing more tissue and lymph nodes surrounding the tumor in the esophagus (known as transthoracic en bloc esophagectomy) offers better control of the cancer than removing less tissue and lymph nodes (known as non-en bloc esophagectomy).

Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer

We hypothesize that one-cycle induction chemotherapy may also help to identify chemo-responsive esophageal cancer patients who are highly treatable by definitive CCRT.

Assessment of a Modified Minimally Invasive Esophagectomy

This is a retrospective case series of a novel fully minimally invasive esophagectomy procedure for patients with primary esophageal cancer.

A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy

Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high. As a result, the thoracoscopic- laparoscopic minimally invasive esophagectomy (MIE) was developed. The MIE mainly comprised two surgical approaches: MIE McKeown approach (cervical anastomosis) and MIE Ivor-Lewis approach (intrathoracicanastomosis). The MIE with intrathoracic anastomosis (Ivor-Lewis) is increasingly used for the treatment ...

Open Versus Laparoscopically-assisted Esophagectomy for Cancer

To compare laparoscopically-assisted gastric mobilization versus open gastric mobilization in Ivor-Lewis esophagectomy for esophageal cancer, with open thoracic approach in the 2 arms.

Esophagectomy: Sweet Versus Ivor-Lewis

Esophageal carcinoma is an aggressive disease with a poor prognosis. Surgical resection remains the basic method of management of this malignancy. Although different approaches have been described for the surgical resection of esophageal cancer, there is no statistical evidence based on large scale prospective randomized trials with regard to the issue that which is the optimal surgical approach for esophageal cancer. The purpose of this study is to test two different approach ...

Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial

The investigators will assess the adequacy of nodal dissection along the recurrent laryngeal nerve performed with robot-assisted versus video-assisted thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma through a prospective multicentre randomized study design.

Perioperative Management and Outcomes of Minimally Invasive Esophagectomy

The investigators retrospectively reviewed the data of all patients who had undergone esophagectomy and reconstruction in 2015. Patient characteristics, the surgery performed, method of anesthesia, postoperative hospitalization course, and additional surgical interventions were reviewed and analyzed.

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.

Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

This is a randomized noninferiority multicenter trial. Patients will be stratified according to the participating hospital. Patients will be randomized to one of the treatment arms. Arm A: Patients will receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy. Arm B: Patients will receive 5-fluorouracil (5-FU) and cisplatin-based chemotherapy concurrently with radiotherapy. Patients will receive cisplatin (60mg/m2)...

Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer

This study is a multi-center, randomized, and open-label trial to compare the safety and feasibility of traditional three incisions and minimally invasive thoracol-laparoscopic esophagectomy for esophageal cancer.

Laparoscopic Ischemic Conditioning Prior to Esophagectomy

This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. In these patients, laparoscopic ischemic conditioning is performed 13-15 days before an Ivor-Lewis esophagectomy. The primary outcome is all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after...

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.

Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage After Esophagectomy for Esophageal Carcinoma.

The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer and gastroesophageal junction cancer.

Cologne Esophageal Response Prediction Study (CERP-Study)

RATIONALE: The prognosis of patients with advanced esophageal cancer may be improved by preoperative chemoradiation. But only those patients have a benefit from this additional therapy, whose tumor shows a response after chemoradiation. Molecular markers may help to identify before starting the therapy those patients who response. PURPOSE: This is the first prospective, clinical trial to study the impact of ERCC1 to predict histopathological response to neoadjuvant radiochemot...

Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma

Definitive chemoradiation is the standard treatment for locally advanced esopahgeal cancer. NCCN recommends radiation dose of 50-50.4Gy as the definitive radiation dose for esophageal cancer with definitive chemoradiation. However, as many studies in China showed that the most common recurrence site after definitive chemoradiation was within the radiation region. But there have not been large randomized clinical trials to investigate the optimal radiation dose with concurrent c...

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surger...

Efficacy of Nasogastric Tube Application in Postoperative Care of Esophagectomy

Nasogastric decompression is standard practice after esophageal resection in most centers because it is expected to reduce the incidence of esophagogastric anastomotic leakage by preventing overdistension of the gastric conduit. Most esophageal surgeons have been reluctant to move away from this tradition because of the considerable morbidity of anastomotic leaks after esophagectomy. However, a contrarian view is that the use of prolonged NGD may increase the incidence of posto...


More From BioPortfolio on "esophagectomy chemoradiation active surveillance Esophageal Cancer"

Quick Search